Mesa Laboratories (MLAB) Expected to Release Earnings on Thursday

Mesa Laboratories (NASDAQ:MLAB) is anticipated to issue its Q2 2027 results after the market closes on Thursday, November 5th. Analysts expect Mesa Laboratories to post earnings of $2.29 per share and revenue of $62.20 million for the quarter. Investors can check the company’s upcoming Q2 2027 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings data on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share for the quarter. Mesa Laboratories had a net margin of 1.92% and a return on equity of 22.72%. The firm had revenue of $60.14 million for the quarter.

Mesa Laboratories Price Performance

NASDAQ MLAB opened at $131.32 on Thursday. Mesa Laboratories has a 52 week low of $69.51 and a 52 week high of $144.35. The company has a current ratio of 1.79, a quick ratio of 1.32 and a debt-to-equity ratio of 0.73. The stock has a market cap of $735.39 million, a price-to-earnings ratio of 156.34 and a beta of 1.06. The company has a 50-day moving average price of $128.08 and a two-hundred day moving average price of $103.52.

Mesa Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 15th. Investors of record on Monday, November 30th will be given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Monday, November 30th. Mesa Laboratories’s dividend payout ratio is currently 76.19%.

Wall Street Analyst Weigh In

MLAB has been the subject of several research reports. Weiss Ratings raised Mesa Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Wall Street Zen raised Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 3rd. Finally, Wells Fargo & Company increased their price target on Mesa Laboratories from $94.00 to $110.00 and gave the company an “equal weight” rating in a research report on Friday, August 14th. Three investment analysts have rated the stock with a Hold rating. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $110.00.

Insider Buying and Selling

In other news, Director R Tripeny acquired 900 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The stock was purchased at an average price of $113.69 per share, with a total value of $102,321.00. Following the purchase, the director owned 6,298 shares of the company’s stock, valued at approximately $716,019.62. This trade represents a 16.67% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Siddhartha Kadia bought 7,093 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was acquired at an average cost of $112.80 per share, with a total value of $800,090.40. Following the transaction, the chief executive officer owned 7,093 shares of the company’s stock, valued at $800,090.40. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 2.80% of the company’s stock.

About Mesa Laboratories

Mesa Laboratories, Inc develops and manufactures products used for quality control, monitoring, and measurement in healthcare, pharmaceutical, industrial, and other regulated applications. The company’s offerings are designed to help customers verify the performance of processes, equipment, and environmental conditions.

Mesa Laboratories’ product portfolio includes sterilization assurance products, such as biological indicators and related monitoring systems, as well as instruments and consumables used in healthcare and laboratory settings.